Functional Data Strengthen Clinical Validation of PhenoScore Phenotype‐Guided AI for ANKRD11 Missense Variants
Clinical Genetics · 2026
DOI: 10.1111/cge.70159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, 2026. Verfasst von Evi Andriessen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Mutation, Missense, Repressor Proteins, Intellectual Disability, Abnormalities, Multiple. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
KBG syndrome (KBGS, OMIM #148050) is a rare genetic disorder caused by heterozygous truncating or missense variants in the ANKRD11 gene or a deletion of 16q24.3 involving ANKRD11 . While truncating variants clearly disrupt protein function, the interpretation of missense variants is more challenging, as many remain variants of uncertain significance (VUS). To address this, we evaluated PhenoScore, an open‐source AI‐based phenomics framework integrating facial recognition and medical data analysis, for predicting the pathogenicity of ANKRD11 missense variants and providing supporting evidence for variant interpretation within the ACMG framework, specifically the PP4 criterion. PhenoScore was trained on 79 individuals with truncating variants in ANKRD11 and age‐, sex‐, and ethnicity‐matched controls with other neurodevelopmental disorders, and its performance was compared to AlphaMissense, REVEL, and the evaluation of a clinical geneticist. Six individuals with functionally confirmed pathogenic missense variants were used for testing. PhenoScore achieved high predictive accuracy with an area under the curve (AUC) of 0.95 and a Brier score of 0.089, and pathogenic missense variants in the test set received a mean prediction score of 0.94. PhenoScore significantly outperformed REVEL ( p < 0.01), especially in cases supported by functional and clinical evidence, while no significant difference was observed compared to AlphaMissense ( p = 0.63); importantly, the two tools showed complementary strengths. These findings suggest that PhenoScore represents a promising tool for clinical variant interpretation, as it quantifies phenotypic concordance with KBGS and provides objective evidence that can strengthen the PP4 criterion within the ACMG framework. Combined with molecular prediction tools like AlphaMissense, PhenoScore may help reduce uncertainty surrounding VUS in ANKRD11 by complementing these scores.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.
- New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, USA.
- The Graduate Center, The City University of New York, New York, New York, USA.
ORCID-Profile: Gholson J Lyon, Charlotte W Ockeloen, Alexander J M Dingemans
Zitieren
APA
Andriessen, E., de Boer, E., Lyon, G. J., de Vries, B. B. A., Ockeloen, C. W., & Dingemans, A. J. M. (2026). Functional Data Strengthen Clinical Validation of PhenoScore Phenotype‐Guided AI for ANKRD11 Missense Variants. Clinical Genetics. https://doi.org/10.1111/cge.70159
Vancouver
Andriessen E, de Boer E, Lyon GJ, de Vries BBA, Ockeloen CW, Dingemans AJM. Functional Data Strengthen Clinical Validation of PhenoScore Phenotype‐Guided AI for ANKRD11 Missense Variants. Clinical Genetics. 2026. doi:10.1111/cge.70159
BibTeX
@article{Andriessen2026,
author = {Andriessen, Evi and de Boer, Elke and Lyon, Gholson J and de Vries, Bert B A and Ockeloen, Charlotte W and Dingemans, Alexander J M},
title = {Functional Data Strengthen Clinical Validation of PhenoScore Phenotype‐Guided AI for ANKRD11 Missense Variants},
journal = {Clinical Genetics},
year = {2026},
doi = {10.1111/cge.70159}
}
EUVIMED